No Data
No Data
UBS Initiates Celldex Therapeutics(CLDX.US) With Buy Rating, Announces Target Price $44
Here's Why We're Not Too Worried About Celldex Therapeutics' (NASDAQ:CLDX) Cash Burn Situation
Celldex Therapeutics And 2 Other Undervalued Small Caps With Insider Action In US
Celldex Therapeutics (NASDAQ:CLDX) Is In A Good Position To Deliver On Growth Plans
Guggenheim Maintains Celldex Therapeutics(CLDX.US) With Buy Rating, Maintains Target Price $90
Citi Maintains Celldex Therapeutics(CLDX.US) With Buy Rating, Maintains Target Price $70